University of Alabama Birmingham
Correction of Sickle Cell Disease by Homologous Recombination
Abstract
dc:description.abstractThe hematological disorder sickle cell disease (SCD) is a prevalent human genetic disease. It causes severe tissue damage that can result in strokes, splenic infarction, kidney failure, liver and lung disorders, painful crises, and other complications. Although palliative therapies and allogenic stem cell transplantation therapies have been developed for this disorder, there is still no optimal treatment and SCD patients continue to suffer significant morbidity. Recently, several powerful technologies have been developed that increase the possibility for developing therapeutic treatments for SCD. Previously, our lab group demonstrated that SCD can be corrected in our humanized mouse model by transduction of hematopoietic stem cells with lentiviral vectors containing an antisickling globin gene. However, concerns about insertional mutagenesis persist. The ideal correction would involve replacement of the sickle globin gene with a normal copy of the beta-globin gene by homologous recombination. Using this technique, we successfully corrected the sickle mutation in a novel knock-in mouse model of SCD. The animals produce high levels of normal human hemoglobin (HbA) and the pathology associated with SCD is corrected. Furthermore, in collaboration with our colleagues at MIT, we recently corrected sickle cell disease in our knockin mouse model by reprogramming skin iii fibroblasts into iPS (induced Pluripotent Stem) cells, replacing the defective sickle betaglobin gene with a normal beta globin gene, differentiating the corrected iPS cells into hematopoietic progenitors and transplanting these cells into irradiated sickle mouse recipients. Over 50% of the hemoglobin in red blood cells of the treated mice was HbA, and the disease was corrected. This is the first demonstration of the use of iPS cells for the successful treatment of a hereditary disease. These experiments provide a foundation the development of a similar strategy to correct sickle cell disease in human patients.
Degree
thesis:*- Level thesis:degree_level
- Dissertation
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Wu, Li-Chen
- Contributors dc:contributor
-
- Tim Townes
- Casey Weaver
- Christopher Klug
- Peter Detloff
- Tom Ryan
Subjects
dc:subject × 1Identifiers
dc:identifier.*- Repository record dc:identifier
- https://digitalcommons.library.uab.edu/etd-collection/289